New York, NY, October 30, 2008 --(PR.com
)-- Preventing oral cancer is the word on the street in New York City, as scores of people are spotting advertisements that are running on hundreds of city buses, inside and out. Oral cancer, which kills twice as many Americans as cervical cancer, is now especially on the rise in young people, women and non-smokers partly due to what is widely suspected to be an oral sex related increase in exposure to the human papilloma virus (HPV). OralCDx Laboratories, a division of Oral Cancer Prevention International, has launched a bus ad campaign, urging people to visit BrushTest certified dentists for this routine screening test. The BrushTest, often compared to the Pap smear for the prevention of cervical cancer, tells patients if any of the common red and white spots that are found in almost everyone’s mouth at one time or another are pre-cancerous and need to be removed, long before they have the chance to develop into cancer.
The ad appears on the outside and inside of 450 MTA buses. Simultaneously, a similar ad jointly placed by OralCDx Laboratories and the American Dental Association is running on over 100 MTA buses.
The bus ads will be running until the end of November, leading into the Greater New York Dental Meeting, taking place at The Javits Center starting on November 28.
Oral cancer, one of the most disfiguring cancers, kills about as many Americans as melanoma and twice as many as cervical cancer. Very few cancers are preventable, and OralCDx is on a mission to let people know that oral cancer has recently joined the short list of preventable cancers. The effectiveness and accuracy of the BrushTest is referenced by both the National Cancer Institute and the ADA, and the test is used by over 30,000 dentists nationwide.
About the BrushTest
OralCDx Laboratories, a division of Oral Cancer Prevention International, Inc., is the worldwide, exclusive provider of the BrushTest, utilizing patented and proprietary tissue sampling and cell analysis systems. The BrushTest is used by dentists and physicians to help prevent oral cancer, a disease that kills as many Americans as melanoma, twice as many as cervical cancer, and is rising among women, young people and non-smokers. Well over 25% of those found to have oral cancer do not use tobacco or abuse alcohol. Recent studies have also shown a link between HPV and an increase in oral cancer.
The BrushTest is taught in the majority of U.S. dental schools and is a covered benefit under Medicare, Medicaid and most private U.S. medical and dental insurance plans. The American Dental Association (ADA), in collaboration with OralCDx Laboratories, has recently embarked on a campaign to inform patients that because of the BrushTest, oral cancer has joined the short list of cancers that can now be stopped, years before they can even start. The accuracy of OralCDx was demonstrated in one of the largest studies in oral medicine ever conducted, performed at 35 academic centers in the U.S., involving nearly 1,000 patients. This study was published as the cover story of the Journal of the American Dental Association and earned OralCDx the ADA’s prestigious Seal of Acceptance.
For more information on the OralCDx BrushTest, call (877) 672-5722 or visit www.BrushTest.com.